Adjuvant therapeutic strategies for resectable pancreatic adenocarcinoma

Of all patients diagnosed with pancreatic adenocarcinoma, only 15–20% present with resectable disease. Despite curative-intent resection, the prognosis remains poor with the majority of patients recurring, prompting the need for adjuvant therapy. Historical data support the use of adjuvant 5-fluorou...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Ann Pancreat Cancer
Asıl Yazarlar: Yegya-Raman, Nikhil, Shah, Mihir M., Grandhi, Miral S., Poplin, Elizabeth, August, David A., Kennedy, Timothy J., Malhotra, Usha, Spencer, Kristen R., Carpizo, Darren R., Jabbour, Salma K.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2018
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6345263/
https://ncbi.nlm.nih.gov/pubmed/30687847
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/apc.2018.07.05
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller